Identifying impurities using advanced analytics
Throughout the course of COVID-19, the market demand for fixed dose combinations (FDCs) used in treatment of fever and common colds has risen significantly. In response to this demand, a number of Recipharm’s customers have had to update their analytical methodologies to ensure they are workable throughout the lifecycle of the drug product.
Recipharm’s protein binding assays help customers to determine which compounds bind to blood proteins. The degree of binding might affect a drug’s efficacy, making it vital to understand this behaviour as early in the project as possible.
Recipharm offers method development and qualification for small molecules and is also embarking on a growing number of projects to develop bioanalytical methods for large molecules, such as oligonucleotides, ADCs, and proteins. The team offers bioanalysis of blood, plasma, cell, and tissue samples from individual compound testing to high throughput screening for multiple compounds, with blood/plasma stability testing playing an important role in drug discovery and development.
In an article with Drug Development & Delivery, Ramesh Jagadeesan, Assistant Vice President at Recipharm, discusses some of the key analytical testing offerings at Recipharm.
Click here to read more.